| Prophylactic treatment (primary prevention) | LVEF HASH(0x2f62220) 35% and NYHA class II-III symptoms after myocardial infarction (HASH(0x2f5d108) 40 days) | 
| LVEF HASH(0x2f62220) 30% and NYHA class I symptoms after myocardial infarction (HASH(0x2f5d108) 40 days) | 
| Nonsustained VT and LVEF HASH(0x2f62220) 40% after myocardial infarction, as well as sustained VT or VF during electrophysiological examination | 
| LVEF HASH(0x2f62220) 35% and NYHA class II-III symptoms or syncope in dilated cardiomyopathy | 
| If considered appropriate by a specialist physician in other structural heart diseases (e.g. hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) and in inherited, potentially life-threatening ion-channel abnormalities (e.g. long QT syndrome, Brugada syndrome, catecholamine-sensitive polymorphic VT) | 
| Treatment post cardiac arrest (secondary prevention) | VT or VF induced cardiac arrest not due to a treatable or reversible cause, even if the heart is structurally normal | 
| Sustained VT in a patient with a structural heart disease, irrespective of the left ventricular function | 
| Unexplained syncope, as well as sustained VT or VF triggered during an electrophysiological examination |